What Is Ozempic For? The FDA-Approved Uses, the Off-Label Uses, and Where the Line Sits in 2026

Key Takeaways

• Ozempic is FDA-approved for adults with type 2 diabetes to improve blood sugar control alongside diet and exercise.
• Ozempic also carries an FDA approval to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established heart disease.
• Ozempic is not FDA-approved for weight loss. The same active ingredient (semaglutide) is FDA-approved for chronic weight management under the brand name Wegovy at a higher dose.
• Off-label prescribing of Ozempic for weight loss is legal but increasingly restricted by insurers and discouraged by the manufacturer.
• Ozempic is a once-weekly subcutaneous injection in doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg.

Direct answer (40-60 words)

Ozempic (semaglutide) is FDA-approved to improve blood sugar in adults with type 2 diabetes and to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who also have known heart disease. It is widely prescribed off-label for weight loss, although that use is not in the FDA label.

Table of contents

1. The 30-second answer
2. The two FDA-approved uses, in plain language
3. How Ozempic works in the body
4. The off-label weight-loss use, and why it became famous
5. Ozempic vs Wegovy: same drug, different label
6. Who should not take Ozempic
7. Dosing: how the drug is started and titrated
8. Common side effects and what to expect
9. Cost, insurance, and the supply situation in 2026
10. FAQ
11. Sources
12. Footer disclaimers

The two FDA-approved uses, in plain language

Ozempic has two FDA approvals, both granted to Novo Nordisk between 2017 and 2020.

Approval 1 (2017): Type 2 diabetes glycemic control. Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In the SUSTAIN trials, semaglutide 1 mg weekly lowered HbA1c by roughly 1.5 to 1.8 percentage points from baseline, more than most older diabetes drugs (Sorli et al., Lancet Diabetes Endocrinol 2017).

Approval 2 (2020): Cardiovascular risk reduction. Ozempic is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease. The SUSTAIN-6 trial showed a 26% relative risk reduction in the composite endpoint over roughly 2 years (Marso et al., NEJM 2016).

Those are the only two indications on the U.S. prescribing information. Anything else, including weight loss in patients without diabetes, is off-label use.

How Ozempic works in the body

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide 1) is a hormone the small intestine releases in response to food. It does several things at once:

1. Tells the pancreas to release more insulin when blood sugar is high (glucose-dependent insulin secretion).
2. Tells the pancreas to release less glucagon, the hormone that pushes glucose out of the liver.
3. Slows gastric emptying, which keeps food in the stomach longer and blunts post-meal blood sugar spikes.
4. Acts on appetite centers in the brain, particularly the hypothalamus, to reduce hunger and increase satiety.

The body's own GLP-1 has a half-life of a few minutes. Semaglutide was engineered to resist enzymatic breakdown and bind to albumin, which extends its half-life to about 7 days. That is why Ozempic is dosed once a week.

For diabetes patients, the insulin and glucagon effects do most of the work on blood sugar. For weight loss, the appetite and gastric-emptying effects do most of the work.

The off-label weight-loss use, and why it became famous

Off-label prescribing means a clinician prescribes an FDA-approved drug for a use other than the FDA-approved indication. It is legal, common, and accounts for roughly 20% of all prescriptions in the United States, per data published by the American Medical Association.

Ozempic became a cultural phenomenon in 2022 and 2023 because clinicians, and patients, noticed that diabetes patients on the drug were losing significant amounts of weight. The STEP 1 trial of semaglutide 2.4 mg (the higher dose later marketed as Wegovy) showed roughly 14.9% mean body-weight reduction over 68 weeks (Wilding et al., NEJM 2021). At Ozempic doses of 1 mg and 2 mg, weight loss is somewhat less but still substantial, around 6 to 11% of body weight depending on dose and adherence.

When Wegovy supply could not keep up with demand from 2022 onward, prescribers and patients turned to Ozempic as a workaround. Insurance coverage rules pushed in the same direction, since many plans cover Ozempic for diabetes but exclude weight-loss drugs.

In 2026, payors are tightening on this. Several large pharmacy benefit managers now require documented type 2 diabetes for Ozempic coverage. Off-label use for weight loss in patients without diabetes is increasingly paid out of pocket.

Ozempic vs Wegovy: same drug, different label

Both Ozempic and Wegovy contain semaglutide. The differences are dose and indication.

A patient prescribed Wegovy for weight loss is using a labeled, FDA-approved indication. A patient prescribed Ozempic for weight loss is using the same molecule off-label at a slightly lower maximum dose. Clinical effect is similar but not identical, because the 0.4 mg difference between the maximum doses produces somewhat more weight loss with Wegovy in head-to-head data.

Who should not take Ozempic

The FDA label lists several contraindications and warnings.

Contraindications (do not take):

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple endocrine neoplasia syndrome type 2 (MEN 2).
• Known serious hypersensitivity to semaglutide or any component of the formulation.

Warnings and precautions:

• Pancreatitis. Discontinue if suspected.
• Diabetic retinopathy complications in patients with a history of diabetic retinopathy.
• Acute kidney injury, particularly in patients with severe nausea, vomiting, or dehydration.
• Hypoglycemia when used with insulin or sulfonylureas.
• Acute gallbladder disease.
• Pregnancy. The drug is not recommended; the manufacturer advises stopping at least 2 months before a planned pregnancy.

The thyroid warning is based on rodent studies showing thyroid C-cell tumors at clinically relevant exposures. Whether the same risk applies in humans is unsettled, which is why the FDA included it as a boxed warning rather than a strict contraindication for all patients.

Dosing: how the drug is started and titrated

Ozempic is a once-weekly subcutaneous injection. The injection sites are the abdomen, thigh, or upper arm. The dose schedule on the label is:

• Weeks 1 to 4: 0.25 mg weekly (starting dose, not therapeutic)
• Weeks 5 to 8: 0.5 mg weekly (first therapeutic dose)
• Weeks 9 to 12: option to increase to 1 mg weekly if more glycemic effect is needed
• Weeks 13+: option to increase to 2 mg weekly if needed

The slow titration is designed to reduce gastrointestinal side effects, which are most common during dose escalation. Most patients tolerate 0.5 mg without trouble, with a noticeable bump in nausea when stepping up to 1 mg or 2 mg.

Doses are taken on the same day each week, with or without food. If a dose is missed, it can be taken within 5 days; if more than 5 days have passed, skip the missed dose and resume the schedule.

Common side effects and what to expect

The side-effect profile of Ozempic in clinical trials, in order of frequency:

Most GI side effects appear during titration and improve within 2 to 4 weeks of staying at a stable dose. Persistent severe nausea or vomiting beyond that window is worth a provider conversation, since it can lead to dehydration and acute kidney injury.

Less common but more serious adverse events from post-marketing surveillance include pancreatitis, gallbladder disease, gastroparesis, and rare cases of severe allergic reaction. Reports filed with the FDA's FAERS database between 2018 and 2024 show a meaningful but small absolute risk for each of these.

Cost, insurance, and the supply situation in 2026

The list price for Ozempic in the United States is roughly $1,000 to $1,100 per monthly pen as of early 2026. Most insured patients pay $25 to $100 per month after coverage. Patients without coverage can use Novo Nordisk's manufacturer savings program, which caps eligible commercial-insurance copays at lower amounts and offers limited cash-pay assistance.

Supply was constrained from 2022 through mid-2024, with intermittent shortages of the 0.5 mg and 1 mg doses. The FDA declared the shortage resolved in late 2024. Compounded semaglutide, which was widely available during the official shortage, is no longer permitted to be produced from non-patient-specific bulk under FDA enforcement guidance, though state-licensed compounding pharmacies may still prepare patient-specific compounds in response to an individual prescription when clinically indicated.

For patients exploring lower-cost or compounded options for related GLP-1 therapies, see our piece on why some clinicians prefer compounded semaglutide for select patients.

FAQ

What is Ozempic actually approved by the FDA to treat? Ozempic is FDA-approved for two things: improving blood sugar in adults with type 2 diabetes, and reducing the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who also have known cardiovascular disease.

Is Ozempic approved for weight loss? No. Ozempic does not carry an FDA weight-loss indication. The same active ingredient is approved for chronic weight management under the brand name Wegovy, at a slightly higher maximum weekly dose. Ozempic is often prescribed off-label for weight loss.

What is the difference between Ozempic and Wegovy? Both are semaglutide made by Novo Nordisk. Ozempic's maximum weekly dose is 2 mg and its label is for diabetes. Wegovy's maximum weekly dose is 2.4 mg and its label is for weight loss. The molecule is the same; the dose ceiling and the official indication differ.

Can a doctor prescribe Ozempic for weight loss? Yes. Off-label prescribing is legal in the United States. A clinician can prescribe an FDA-approved drug for a non-labeled use when they judge it medically appropriate. Insurance coverage for off-label weight-loss use of Ozempic is increasingly restricted, so many patients pay out of pocket.

Does Ozempic work without diet and exercise? Ozempic produces some weight loss and blood-sugar improvement on its own, but the FDA label and clinical trials specify that it is meant to be used alongside diet and exercise. Patients who pair the medication with reduced-calorie eating and regular physical activity see meaningfully better outcomes.

How long do you stay on Ozempic? For diabetes, Ozempic is typically a long-term, ongoing medication. Stopping the drug usually leads to blood-sugar levels rising back toward where they were before treatment. The same pattern is seen with weight, where most patients regain a substantial portion of lost weight within a year of discontinuation.

Is Ozempic the same as insulin? No. Insulin is the hormone the pancreas produces to lower blood sugar directly. Ozempic is a GLP-1 receptor agonist, which prompts the body to release its own insulin in response to food and reduces glucagon secretion. The two drug classes can be used together but work through different mechanisms.

Can people without diabetes take Ozempic? A clinician can prescribe Ozempic to a person without diabetes for off-label weight management. Whether they should is a clinical judgment that weighs benefit against side effects and access to alternatives like Wegovy, which has a labeled weight-loss indication.

What happens if I miss a weekly Ozempic dose? If you remember within 5 days, take the missed dose as soon as possible and continue your normal weekly schedule. If more than 5 days have passed, skip the missed dose and take the next one on your regular day. Do not double up.

Does Ozempic cause hair loss? Hair loss is reported by a small percentage of patients, particularly during periods of rapid weight loss. The hair loss is typically telogen effluvium, the same kind of shedding that follows any major caloric or stress shift, and it usually reverses within 6 to 12 months once weight stabilizes.

Is Ozempic safe long-term? The longest controlled trial data extends to roughly 5 years for related semaglutide products. Within that window, the safety signal has been consistent with the labeled adverse-event profile. Truly long-term (10+ year) human safety data does not yet exist for any GLP-1 receptor agonist.

Does Ozempic interact with other drugs? Ozempic slows gastric emptying, which can change how quickly other oral medications are absorbed. Insulin and sulfonylureas raise the risk of hypoglycemia when combined with Ozempic. Patients on warfarin, oral contraceptives, or thyroid medication should let their prescriber know they are starting a GLP-1 drug.

Sources

1. Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5:251-260.
2. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Davies MJ, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
5. Ozempic prescribing information. Novo Nordisk. Plainsboro, NJ. Revised 2024.
6. Wegovy prescribing information. Novo Nordisk. Plainsboro, NJ. Revised 2024.
7. American Medical Association. Off-label prescribing policy statement. AMA Code of Medical Ethics, Opinion 1.1.7.
8. FDA Adverse Event Reporting System (FAERS) Public Dashboard. U.S. Food and Drug Administration. Accessed 2026.
9. FDA Drug Shortages list. Semaglutide injection products. U.S. Food and Drug Administration. Resolved status confirmed October 2024.
10. Lingvay I, et al. Effect of once-weekly semaglutide on body weight in subjects with obesity and type 2 diabetes (STEP 2 sub-analysis). Diabetes Obes Metab. 2022;24:1463-1472.
11. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.